tipapkinogene sovacivec
AXP000182.1 · Cancer vaccine
- Platform
- MVA
- Originator
- Transgene
- Sponsor
- Transgene
Names
| Name | Type | Source |
|---|---|---|
| tipapkinogene sovacivec | preferred name | curator |
| TG4001 | code | ncit |
| MVA-HPV-IL2 | synonym | ncit |
| MVA-HPV16E6/E7-IL2 | synonym | ncit |
| RG3484 | former code | ncit |
| RO5217790 | former code | ncit |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA
- Replication
- non replicating
- Modifications
- HPV-16 E6, HPV-16 E7 and IL-2 cassettes inserted into MVA
- Transgenes
- HPV-16 E6, HPV-16 E7, IL2
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C88326
- FDA UNII
- P34L5Y2SR5
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | Active not recruiting | Phase 1/2 | 2017-09-01 | 2024-09-18 | 143 | HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Penile Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma |
| NCT01022346 | A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection | Completed | Phase 2 | 2009-08 | 2013-09 | 206 | Cervical Intraepithelial Neoplasia |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37506588 | Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. | European journal of cancer (Oxford, England : 1990) | 2023 | cited by trial NCT03260023 |
| PMID 21284968 | Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. | American journal of obstetrics and gynecology | 2011 | name in title: TG4001 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41294662 | Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials. | Current oncology (Toronto, Ont.) | 2025 | name in abstract: TG4001 |
Notes
TG4001: MVA encoding HPV-16 E6 and E7 plus human IL-2, for HPV16-positive cancers; phase 1b/2 and a randomised phase 2 with avelumab (missed its primary endpoint, reported 2024). Also carried the Roche codes RO5217790/R3484. E6/E7 are deleted/detoxified in some descriptions; modification detail not verified here.
How to cite
tipapkinogene sovacivec (AXP000182.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000182.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.